State of the art and perspectives in pediatric hepatocellular carcinoma

Digiacomo, Graziana; Serra, Roberta Pia; Turrini, Elena; Tiri, Alessandra; Cavazzoni, Andrea; Alfieri, Roberta; Bertolini, Patrizia

doi:10.1016/j.bcp.2022.115373

Cited by 6 publications

(7 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The etiology of HB is unknown, but is associated with very low birth weight and various genetic disorders [ 210 ]. In contrast, most cases of HCC are adult-onset, with only a few pediatric cases, accounting for only 0.4 cases per million children aged 0–14 years [ 211 ]. Unlike adults, the etiology is unclear in most pediatric cases [ 208 ].…”

Section: Cisplatin For Pediatric Liver Tumorsmentioning

confidence: 99%

“…Unlike adults, the etiology is unclear in most pediatric cases [ 208 ]. However, HCC occurring in underlying liver disease includes infections, such as HBV, and metabolic diseases, such as tyrosinemia and Alagille syndrome, with causes having regional variations depending on the prevalence of HBV [ 208 , 211 , 212 ].…”

Section: Cisplatin For Pediatric Liver Tumorsmentioning

confidence: 99%

“…Preoperative and postoperative chemotherapy and surgical approaches including hepatectomy and liver transplantation are effective in the treatment of HB and HCC [ 211 ]. HB combined with preoperative and postoperative chemotherapy has greatly improved outcomes [ 209 ].…”

Section: Cisplatin For Pediatric Liver Tumorsmentioning

confidence: 99%

See 2 more Smart Citations

Cisplatin in Liver Cancer Therapy

Hamaya

Oura

Morishita

et al. 2023

IJMS

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most common primary liver tumor and is often diagnosed at an unresectable advanced stage. Systemic chemotherapy as well as transarterial chemoembolization (TACE) and hepatic arterial infusion chemotherapy (HAIC) are used to treat advanced HCC. TACE and HAIC have long been the standard of care for patients with unresectable HCC but are limited to the treatment of intrahepatic lesions. Systemic chemotherapy with doxorubicin or chemohormonal therapy with tamoxifen have also been considered, but neither has demonstrated survival benefits. In the treatment of unresectable advanced HCC, cisplatin is administered transhepatic arterially for local treatment. Subsequently, for cisplatin-refractory cases due to drug resistance, a shift to systemic therapy with a different mechanism of action is expected to produce new antitumor effects. Cisplatin is also used for the treatment of liver tumors other than HCC. This review summarizes the action and resistance mechanism of cisplatin and describes the treatment of the major hepatobiliary cancers for which cisplatin is used as an anticancer agent, with a focus on HCC.

show abstract

Section: Cisplatin For Pediatric Liver Tumorsmentioning

confidence: 99%

Section: Cisplatin For Pediatric Liver Tumorsmentioning

confidence: 99%

See 1 more Smart Citation

Cisplatin in Liver Cancer Therapy

Hamaya

Oura

Morishita

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Z negenetických onemocnění lze uvést autoimunitní hepatitidu a méně často infekční hepatitidy. (9,10,11) Ve velkém retrospektivním souboru pacientů s TYR 1, který zahrnoval i české pacienty, byla transplantace jater indikována u 29/168 dětí. Hlavní indikací k transplantaci jater byl v 72 % HCC, dále cirhóza jater a jaterní selhání.…”

Section: Diskuseunclassified

Hepatocellular carcinoma in an infant with tyrosinemia type 1

Kelifová¹,

Honzík²,

Tesařová³

et al. 2023

Ces-slov Pediat

View full text Add to dashboard Cite

“…7 In children with HCC, overall 5-year survival rate is less than 30%, as compared with less than 10% in adults with HCC. 8 9 Other pediatric hepatic malignancies include hepatocellular malignant neoplasm not otherwise specified (which combines the histological features of hepatoblastoma and HCC), fibrolamellar HCC, sarcomas (e.g., undifferentiated embryonal sarcoma, biliary rhabdomyosarcoma, and angiosarcomas), cholangiocarcinoma, germ cell tumor, and rhabdoid tumor and metastatic tumors (neuroblastoma, Wilms tumor), comprise the remainder of liver malignancies. Fibrolamellar HCC, a variant seen in adolescents and young adults without underlying liver disease, accounts for about a third of HCC patients younger than 20 years.…”

mentioning

confidence: 99%

Interventional Radiology Management of Pediatric Liver Tumors

Kim,

Shaikh

2024

Digestive Disease Interventions

View full text Add to dashboard Cite

Pediatric liver tumors are not only rare, they are also different from the adult liver tumors. Hepatoblastomas and hepatocellular carcinomas (HCCs) are the most common primary malignant tumors seen in children. Fibrolamellar HCC, sarcomas, cholangiocarcinoma, germ cell tumor, and rhabdoid tumor and metastatic tumors comprise the remainder of liver malignancies. Hepatic infantile hemangiomas, mesenchymal hamartoma, regenerative nodules, adenomas, and focal nodular hyperplasia are the common benign liver tumors of childhood. The Pediatric Hepatic International Tumour Trial (PHITT) is an international trial with the goal of evaluating new and existing treatments for pediatric liver tumors. Chemotherapy, surgery, and liver transplantation are well-established in the management of pediatric liver tumors. In the background of increasing incidence of pediatric tumors, and availability of newer, less invasive modalities to treat tumors, it is vital to understand the role of interventional radiology in the management of pediatric liver tumors.

show abstract

State of the art and perspectives in pediatric hepatocellular carcinoma

Cited by 6 publications

References 76 publications

Cisplatin in Liver Cancer Therapy

Cisplatin in Liver Cancer Therapy

Hepatocellular carcinoma in an infant with tyrosinemia type 1

Interventional Radiology Management of Pediatric Liver Tumors

Contact Info

Product

Resources

About